OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry
Tim Spelman, Serkan Özakbaş, Raed Alroughani, et al.
Multiple Sclerosis Journal (2022) Vol. 29, Iss. 2, pp. 221-235
Open Access | Times Cited: 21
Tim Spelman, Serkan Özakbaş, Raed Alroughani, et al.
Multiple Sclerosis Journal (2022) Vol. 29, Iss. 2, pp. 221-235
Open Access | Times Cited: 21
Showing 21 citing articles:
Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing–remitting multiple sclerosis patients: a monocentric longitudinal observational study
Chiara Zanetta, Maria A. Rocca, Alessandro Meani, et al.
Journal of Neurology (2023) Vol. 270, Iss. 7, pp. 3553-3564
Open Access | Times Cited: 18
Chiara Zanetta, Maria A. Rocca, Alessandro Meani, et al.
Journal of Neurology (2023) Vol. 270, Iss. 7, pp. 3553-3564
Open Access | Times Cited: 18
Ongoing phase 2 agents for multiple sclerosis: could we break the phase 3 trial deadlock?
Sílvia Susin-Calle, José Rodríguez, Elvira Munteis, et al.
Expert Opinion on Investigational Drugs (2025)
Closed Access
Sílvia Susin-Calle, José Rodríguez, Elvira Munteis, et al.
Expert Opinion on Investigational Drugs (2025)
Closed Access
Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis
Rosa Cortese, Giovanna Testa, Francesco Assogna, et al.
CNS Drugs (2024) Vol. 38, Iss. 4, pp. 267-279
Open Access | Times Cited: 4
Rosa Cortese, Giovanna Testa, Francesco Assogna, et al.
CNS Drugs (2024) Vol. 38, Iss. 4, pp. 267-279
Open Access | Times Cited: 4
Real‐world persistence of multiple sclerosis disease‐modifying therapies
Emma Tallantyre, Ruth Dobson, Joseph L. J. Froud, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 7
Open Access | Times Cited: 4
Emma Tallantyre, Ruth Dobson, Joseph L. J. Froud, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 7
Open Access | Times Cited: 4
Administration and Monitoring Burden of High-Efficacy Disease-Modifying Therapies for Multiple Sclerosis: A Delphi Consensus of Clinical Experts from Saudi Arabia
Seraj Makkawi, Ahmad Abulaban, Yaser Al Malik, et al.
Neurology and Therapy (2025)
Open Access
Seraj Makkawi, Ahmad Abulaban, Yaser Al Malik, et al.
Neurology and Therapy (2025)
Open Access
Real World Experience with Cladribine Tablets for Multiple Sclerosis at Four Academic Multiple Sclerosis Centers
Devon Conway, Jacqueline A. Nicholas, Nicolas R. Thompson, et al.
Multiple Sclerosis and Related Disorders (2025) Vol. 94, pp. 106272-106272
Closed Access
Devon Conway, Jacqueline A. Nicholas, Nicolas R. Thompson, et al.
Multiple Sclerosis and Related Disorders (2025) Vol. 94, pp. 106272-106272
Closed Access
Additional Cladribine Tablets Treatment Courses in Multiple Sclerosis Patients. A Retrospective Observational Study in Latin American Countries
Berenice Silva, María Célica Ysrraelit, Gisela Zanga, et al.
Multiple Sclerosis and Related Disorders (2025) Vol. 94, pp. 106275-106275
Closed Access
Berenice Silva, María Célica Ysrraelit, Gisela Zanga, et al.
Multiple Sclerosis and Related Disorders (2025) Vol. 94, pp. 106275-106275
Closed Access
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
Izanne Roos, Sifat Sharmin, Charles B. Malpas, et al.
Multiple Sclerosis Journal (2024) Vol. 30, Iss. 9, pp. 1163-1175
Closed Access | Times Cited: 2
Izanne Roos, Sifat Sharmin, Charles B. Malpas, et al.
Multiple Sclerosis Journal (2024) Vol. 30, Iss. 9, pp. 1163-1175
Closed Access | Times Cited: 2
Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study
Wallace Brownlee, Aiden Haghikia, Brooke Hayward, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 76, pp. 104791-104791
Open Access | Times Cited: 6
Wallace Brownlee, Aiden Haghikia, Brooke Hayward, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 76, pp. 104791-104791
Open Access | Times Cited: 6
Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study
Wallace Brownlee, Amerah Amin, Luke Ashton, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 79, pp. 104951-104951
Open Access | Times Cited: 6
Wallace Brownlee, Amerah Amin, Luke Ashton, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 79, pp. 104951-104951
Open Access | Times Cited: 6
Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic
Adam Stȩpień, Aleksandra Pogoda-Wesołowska, E Tokarz-Kupczyk, et al.
Neurologia i Neurochirurgia Polska (2023) Vol. 57, Iss. 4, pp. 371-378
Open Access | Times Cited: 4
Adam Stȩpień, Aleksandra Pogoda-Wesołowska, E Tokarz-Kupczyk, et al.
Neurologia i Neurochirurgia Polska (2023) Vol. 57, Iss. 4, pp. 371-378
Open Access | Times Cited: 4
Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States
Yan Song, Yan Wang, Schiffon L. Wong, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 79, pp. 105052-105052
Open Access | Times Cited: 4
Yan Song, Yan Wang, Schiffon L. Wong, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 79, pp. 105052-105052
Open Access | Times Cited: 4
Holistic, Long-Term Management of People with Relapsing Multiple Sclerosis with Cladribine Tablets: Expert Opinion from France
Jonathan Ciron, Bertrand Bourre, Giovanni Castelnovo, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 3, pp. 503-518
Open Access | Times Cited: 1
Jonathan Ciron, Bertrand Bourre, Giovanni Castelnovo, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 3, pp. 503-518
Open Access | Times Cited: 1
Real-World Effectiveness and Safety of Cladribine in Multiple Sclerosis: Longitudinal Data From the Nationwide Registry in Argentina
Juan Ignacio Rojas, Ricardo Alonso, Geraldine Luetic, et al.
Clinical Neuropharmacology (2024) Vol. 47, Iss. 4, pp. 120-127
Closed Access | Times Cited: 1
Juan Ignacio Rojas, Ricardo Alonso, Geraldine Luetic, et al.
Clinical Neuropharmacology (2024) Vol. 47, Iss. 4, pp. 120-127
Closed Access | Times Cited: 1
The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis
Helmut Butzkueven, Jan Hillert, Merja Soilu‐Hänninen, et al.
Current Medical Research and Opinion (2023) Vol. 39, Iss. 10, pp. 1367-1374
Open Access | Times Cited: 3
Helmut Butzkueven, Jan Hillert, Merja Soilu‐Hänninen, et al.
Current Medical Research and Opinion (2023) Vol. 39, Iss. 10, pp. 1367-1374
Open Access | Times Cited: 3
Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase
Tim Spelman, Sara Eichau, Raed Alroughani, et al.
Multiple Sclerosis Journal - Experimental Translational and Clinical (2024) Vol. 10, Iss. 2
Open Access
Tim Spelman, Sara Eichau, Raed Alroughani, et al.
Multiple Sclerosis Journal - Experimental Translational and Clinical (2024) Vol. 10, Iss. 2
Open Access
Experience with the use of cladribine tablets in real-life clinical practice: independent analysis of data from 12 Russian clinical centres
Alexey Boyко, В. М. Алифирова, D. V. Pashkovskaya, et al.
Neurology neuropsychiatry Psychosomatics (2024) Vol. 16, pp. 44-50
Open Access
Alexey Boyко, В. М. Алифирова, D. V. Pashkovskaya, et al.
Neurology neuropsychiatry Psychosomatics (2024) Vol. 16, pp. 44-50
Open Access
Cladribine use trend in Latin America: the changes in patient profile impact in the drug effectiveness
Berenice Silva, Alejandra Heriz, Jeremías Ayerbe, et al.
Neurological Sciences (2024)
Closed Access
Berenice Silva, Alejandra Heriz, Jeremías Ayerbe, et al.
Neurological Sciences (2024)
Closed Access
Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals
Ardra Shephard, Laura Kolaczkowski, Noreen Barker, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 4, pp. 1015-1038
Open Access
Ardra Shephard, Laura Kolaczkowski, Noreen Barker, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 4, pp. 1015-1038
Open Access
Practical Recommendations from the Gulf Region on the Therapeutic Use of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis: Impact of the Latest Real-World Evidence on Clinical Practice
Bassem Yamout, Raed Alroughani, Jihad Inshasi, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 5, pp. 1321-1335
Open Access
Bassem Yamout, Raed Alroughani, Jihad Inshasi, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 5, pp. 1321-1335
Open Access
Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment
Albert Muñoz‐Vendrell, Pablo Arroyo-Pereiro, Isabel León, et al.
Journal of Neurology (2023) Vol. 270, Iss. 5, pp. 2559-2566
Open Access
Albert Muñoz‐Vendrell, Pablo Arroyo-Pereiro, Isabel León, et al.
Journal of Neurology (2023) Vol. 270, Iss. 5, pp. 2559-2566
Open Access
